Latest Interstitial lung disease Stories
Expert from the University of California San Francisco, regarded as one the world's leading academic centers in health sciences, will lead a discussion on pulmonary fibrosis in scleroderma.
First FDA Approved Treatments in United States for Devastating Lung Disease Affecting More than 200,000 Americans, with Survival Rate of Just Three to Five Years CHICAGO, Oct.
MORRISTOWN, N.J., Aug. 5, 2014 /PRNewswire/ -- Moerae Matrix, Inc.
CHICAGO, June 10, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced a key partnership with Biogen Idec in support of the PFF Patient Registry.
Classifier shows promise for differentiating IPF from other interstitial lung diseases SOUTH SAN FRANCISCO, Calif., May 20, 2014 /PRNewswire/ --
-- Two Phase 3 trials met primary endpoint of reduction in annual rate of lung function decline RIDGEFIELD, Conn., May 18, 2014 /PRNewswire/ -- Boehringer Ingelheim announced the results of
BRISBANE, Calif., May 16, 2014 /PRNewswire/ -- InterMune, Inc.
SAN DIEGO, April 21, 2014 /PRNewswire/ -- Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs.
CHICAGO, March 27, 2014 /PRNewswire-USNewswire/ -- Patients with pulmonary fibrosis (PF), their caregivers, family members, and health care providers will now be able to access a centralized
Chief Medical Officer and Chairman of the Steering Committee for the PFF Care Center Network and PFF Patient Registry Announced CHICAGO, Feb.
- A trick or prank.